Which country is Trametinib (Megenin) produced in and the information about the original manufacturer?

Trametinib (Trametinib, trade name: Mekinist) is a highly selective MEK Inhibitor, mainly acts on MEK1 and MEK2kinases in the MAPK/ERK signaling pathway. The drug was developed to treat malignant melanoma with BRAF V600 mutations, and is often used clinically in combination with the BRAF inhibitor dabrafenib (Dabrafenib) to improve efficacy and delay the occurrence of drug resistance. The birth of trametinib is an important achievement in the field of precision tumor treatment.

Trametinib was initially developed by Australian pharmaceutical company Metabasis Therapeutics and was later acquired and further developed by GlaxoSmithKline (GlaxoSmithKline, GSK). Finally, GSK completed clinical research and global application for the drug, and was approved by the US FDA in 2013. Therefore, the original manufacturer of trametinib is the British multinational pharmaceutical company GlaxoSmithKline (GSK), with production locations covering the United States and some European factories.

Trametinib was approved in the United States in 2013, becoming the first MEK inhibitor approved by the FDA. Subsequently, it was successively approved in the European Union, Australia, Japan and other countries and regions, and gradually entered clinical application. It is typically used alone or in combination with dabrafenib to treat patients with BRAF V600E/K mutation-positive melanoma, non-small cell lung cancer, and thyroid cancer. Due to GSK's global production and distribution network, trametinib has a relatively stable supply in the international market and has become an important part of targeted tumor therapy.

In China, trametinib has been approved for marketing by the National Food and Drug Administration (NMPA), and its main indication is BRAF V600 Mutated unresectable or metastatic melanoma, and is often used in combination with dabrafenib. Because it is an original drug, the price is relatively high. However, with the policy promotion and negotiations on importing drugs into medical insurance in recent years, its accessibility is gradually improving. Patients can obtain a doctor's prescription in a regular hospital and purchase drugs through legal channels, thus benefiting from this internationally leading targeted treatment program.

Reference materials:https://www.drugs.com/